Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;8(3):371-386.
doi: 10.14283/jpad.2021.23.

Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021

Affiliations
Review

Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021

A P Porsteinsson et al. J Prev Alzheimers Dis. 2021.

Abstract

Alzheimer's disease is a progressive, irreversible neurodegenerative disease impacting cognition, function, and behavior. Alzheimer's disease progresses along a continuum from preclinical disease, to mild cognitive and/or behavioral impairment and then Alzheimer's disease dementia. Recently, clinicians have been encouraged to diagnose Alzheimer's earlier, before patients have progressed to Alzheimer's disease dementia. The early and accurate detection of Alzheimer's disease-associated symptoms and underlying disease pathology by clinicians is fundamental for the screening, diagnosis, and subsequent management of Alzheimer's disease patients. It also enables patients and their caregivers to plan for the future and make appropriate lifestyle changes that could help maintain their quality of life for longer. Unfortunately, detecting early-stage Alzheimer's disease in clinical practice can be challenging and is hindered by several barriers including constraints on clinicians' time, difficulty accurately diagnosing Alzheimer's pathology, and that patients and healthcare providers often dismiss symptoms as part of the normal aging process. As the prevalence of this disease continues to grow, the current model for Alzheimer's disease diagnosis and patient management will need to evolve to integrate care across clinical disciplines and the disease continuum, beginning with primary care. This review summarizes the importance of establishing an early diagnosis of Alzheimer's disease, related practical 'how-to' guidance and considerations, and tools that can be used by healthcare providers throughout the diagnostic journey.

Keywords: Alzheimer’s disease; diagnostic work-up; early diagnosis.

PubMed Disclaimer

Conflict of interest statement

AP reports personal fees from Acadia Pharmaceuticals, Alzheon, Avanir, Biogen, Cadent Therapeutics, Eisai, Functional Neuromodulation, MapLight Therapeutics, Premier Healthcare Solutions, Sunovion, and Syneos; grants from Alector, Athira, Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, and Vaccinex. RI has nothing to disclose. MS reports personal fees from Alzheon, Athira, Biogen, Cortexyme, Danone, Neurotrope, Regeneron, Roche-Genentech, and Stage 2 Innovations; stock options from Brain Health Inc, NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMethod Health, and Versanum Inc. Additionally, he has intellectual property rights with Harper Collins. SK and IR report employment with Biogen.

Figures

Figure 1
Figure 1
Stages within the Alzheimer's disease continuum
Figure 2
Figure 2
A stepwise infographic to highlight key stages within the diagnostic process, along with the recommended tests to support each step

References

    1. Hughes J. This is one of the biggest global health crises of the 21st century. World Econ Forum. 2017 https://www.weforum.org/agenda/2017/09/dementia-trillion-dollar-global-c...
    1. Alzheimer's Disease International World Alzheimer Report 2019. Attitudes to dementia. 2019. https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf
    1. Alzheimer's Association 2020 Alzheimer's disease facts and figures. Alzheimers Dement. 2020;16:391–460. 10.1002/alz.12068 - DOI
    1. Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing alzheimer's disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res. 2017;17:189–202. 10.1080/14737167.2017.1313118 PubMed PMID: 28351177, PMCID 5494694. - DOI - PMC - PubMed
    1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189. 10.1101/cshperspect.a006189 PubMed PMID: 22229116, PMCID 3234452. - DOI - PMC - PubMed